Axcella Health — Investor Presentation (January 2022)
36 slides from Axcella Health's investor presentation, Jan 10, 2022
Slide 1: Axcella Therapeutics Investor Presentation January 2022
© 2022 Axcella Therapeutics. All rights reserved. NASDAQ: AXLA Axcella Therapeutics Investor Presentation January 2022
Slide 2: Forward-Looking Statements
© 2022 Axcella Therapeutics. All rights reserved. Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding the characteristics, competit
Slide 3: Axcella seeks to be a world's leading developer of endogenously-powered therapies
© 2022 Axcella Therapeutics. All rights reserved. Axcella seeks to be a world’s leading developer of multi-targeted, endogenously-powered therapies that address the needs of patients with a range of complex diseases. Advanced and validated process to design Endogenous Metabolic Modulator (EMM) compo
Slide 4: Multi-Targeted Therapeutics to Restore Homeostasis
© 2022 Axcella Therapeutics. All rights reserved. • Complex conditions are driven by dysregulation in multiple biological pathways, limiting the effect of single-targeted therapies • Amino acid-based therapeutics can be safely used to: — Regulate key signaling pathways — Restore mitochondrial functi
Slide 5: A Highly Informed Candidate Design Process
© 2022 Axcella Therapeutics. All rights reserved. A Highly Informed Candidate Design Process Discover Identify target biologies/ indications Prioritize Rank and select potential opportunities Design Select EMM constituents Optimize Refine candidates for clinical investigation Translate Validate safe
Slide 6: Key Capability: Restoring Mitochondrial and Bioenergetic Function
© 2022 Axcella Therapeutics. All rights reserved. Key Capability: Restoring Mitochondrial and Bioenergetic Function Mitochondria act as the cellular “powerhouse” Axcella has demonstrated a potential to restore mitochondrial function and cellular homeostasis with AXA1125 • Mitochondria help to regula
Slide 7: Expected 2022 Milestones
© 2022 Axcella Therapeutics. All rights reserved. Milestone timing based on current expectations and subject to change. * Assumes positive Phase 2a data readout. Expected 2022 Milestones 7 Program Update Timing AXA1125 for Long COVID Phase 2a Enrollment Completion 1H 2022 Phase 2a Top-Line Data Mid-
Slide 8: AXA1125 for Long COVID
© 2022 Axcella Therapeutics. All rights reserved. AXA1125 for Long COVID 8
Slide 9: Long COVID: An Enormous and Still Emerging Public Health Crisis
© 2022 Axcella Therapeutics. All rights reserved. 1. WHO Coronavirus (COVID-19) Dashboard: https://covid19.who.int/ 2. A Detailed Study of Patients with Long-Haul COVID, A FAIR Health White Paper, June 15, 2021 3. American Academy of Physical Medicine and Rehabilitation’s “PASC Dashboard”. PASC = Po
Slide 10: Mitochondrial Dysregulation and Inflammation Implicated in Long COVID Fatigue
© 2022 Axcella Therapeutics. All rights reserved. Mitochondrial Dysregulation and Inflammation are Increasingly Being Implicated in Long COVID Fatigue/Muscle Weakness Emerging scientific data 10
Slide 11: Mitochondrial Cascade in Long COVID
© 2022 Axcella Therapeutics. All rights reserved. Top right: Nat Cell Biol. 2018 July, 20(7): 745–754; Bottom right: Immunity & Ageing (2020) 17:33 Cell Metabolism 32, 437–446 Mitochondrial Cascade in Long COVID Result of Mitochondrial Dysfunction and Inflammation in Long Covid Cascade of effects, i
Slide 12: AXA1125 Drives Improvement in Mitochondrial Respiration
© 2022 Axcella Therapeutics. All rights reserved. AXA1125 Drives Improvement in Mitochondrial Respiration *: p<0.05 **: p<0.01, ***: p<0.001 Fatty Acid Oxidation, Basal Respiration ATP Production FFA FFA + A X A 11 25 (5 X ) FFA + A X A 11 25 (1 5X ) FFA + A X A 11 25 (3 0X ) -60 -40 -20 0 20 40
Slide 13: Increased Fatty Acid Oxidation with AXA1125
© 2022 Axcella Therapeutics. All rights reserved. 14.80 16.38 18.41 0 5 10 15 20 FFA AXA1125 (10X) AXA1125 (30X) A c e ty l- C o A M 2 L a b e li n g ( % ) Data shown above were generated in vitro with the same AA constituents of AXA1125, i.e. LIVRQNac, at a multiple of their baseline concentrations
Slide 14: AXA1125 Improves Mitochondrial Energetics and Anti-Inflammatory Profile
© 2022 Axcella Therapeutics. All rights reserved. Data shown above were generated in vitro with the same AA constituents of AXA1125, i.e. LIVRQNac, at a multiple of their baseline concentrations as found in the Human Metabolome Database. FFA, free fatty acid; HIF-1, hypoxia-inducible factor 1; LIVRQ
Slide 15: Impact of AXA1125 on Mitochondrial Function Matches Clinical Need in Long COVID
© 2022 Axcella Therapeutics. All rights reserved. Impact of AXA1125 on Mitochondrial Function Matches Key Science and Clinical Need in Long COVID Evidence of mitochondrial dysfunction in NASH and Long COVID 15 Result of Mitochondrial Dysfunction and Inflammation in Long Covid Cascade of effects, inc
Slide 16: Phase 2a Long COVID Clinical Trial Now Underway
© 2022 Axcella Therapeutics. All rights reserved. BID, twice daily; MRS, magnetic resonance spectroscopy; PCr, phophocreatine; PRO, patient reported outcomes Phase 2a Long COVID Clinical Trial Now Underway Top-line data anticipated in mid-2022 Screening 1:1 Randomization (N=~40) AXA1125 33.9g BID (6
Slide 17: Reduction in Skeletal Muscle PCr Leads to Improved Muscle Function
© 2022 Axcella Therapeutics. All rights reserved. 1. Gamboa et al. CJASN (July 2020) Vol 15 2. Oorschot et al. PLOS ONE (Sept. 2013) Vol 8 Issue 9 3. Zane et al. Aging Cell (2017) 16, pp461–468 Reduction in Skeletal Muscle PCr Leads to Improved Muscle Function PCr recovery time after exercise reflec
Slide 18: AXA1125 for Nonalcoholic Steatohepatitis (NASH)
© 2022 Axcella Therapeutics. All rights reserved. AXA1125 for Nonalcoholic Steatohepatitis (NASH) 18
Slide 19: Nonalcoholic Steatohepatitis (NASH)
© 2022 Axcella Therapeutics. All rights reserved. 1. Desai, R. et al. Characterization of Polypharmacy in Patients with NAFLD. AASLD 2018 2. Global Liver Institute U.S. NASH Action Plan (Dec. 2020). 3. Younossi, Z. et al. Hepatology. Vol. 64, No. 1, 2016. Nonalcoholic Steatohepatitis (NASH) A comple
Slide 20: AXA1125 - Designed to Target Multiple Metabolic Pathways
© 2022 Axcella Therapeutics. All rights reserved. Hypothesized mechanisms depicted above. AAs, amino acids; AMPK, AMP-activated protein kinase; Arg, arginine; Gln, glutamine; GSH, glutathione; Hif1α, hypoxia-inducible factor 1 alpha; GSH, glutathione; Ile, isoleucine; Leu, leucine; Nac, N-acetylcyst
Slide 21: AXA1125 NASH biomarker results
© 2022 Axcella Therapeutics. All rights reserved. -0.7 -3.5-3.4 -5.3 -9 -6 -3 0 All Subjects Subjects with T2D A b s o lu te c h a n g e , m e a n ( S E ), n g / m L ProC3 -1.9 -21.4 -7.5 -16.2 -45 -30 -15 0 All Subjects Subjects with T2D R e la ti v e c h a n g e , m e a n ( S E ), % FIB-4 18.3 -42
Slide 22: AXA1125: Meaningful Thresholds of Activity Achieved
© 2022 Axcella Therapeutics. All rights reserved. 33.0 45.5 0 10 20 30 40 50 S u b je c ts , % 33.0 63.6 0 10 20 30 40 50 60 70 S u b je c ts , % 0.0 54.5 0 20 40 60 S u b je c ts , % 1. Loomba, R. et al. Hepatology (January 2020). 2. Loomba, R. et al. Gastroenterology (January 2019). 3. Dennis, A.
Slide 23: Phase 2b Clinical Trial Underway
© 2022 Axcella Therapeutics. All rights reserved. D1: Biopsy Fibroscan MRI-PDFF W48: Biopsy Fibroscan MRI-PDFF W24: Fibroscan MRI-PDFF W12: Fibroscan MRI-PDFF Phase 2b Clinical Trial Underway Interim analysis expected in mid-2022 Screening 1:1:1 Randomization (N=~270) 8 WEEKS AXA1125 22.6g BID (45.2
Slide 24: AXA1665 for Overt Hepatic Encephalopathy (OHE)
© 2022 Axcella Therapeutics. All rights reserved. AXA1665 for Overt Hepatic Encephalopathy (OHE) 24
Slide 25: Overt Hepatic Encephalopathy (OHE)
© 2022 Axcella Therapeutics. All rights reserved. 1. Company estimates based on Scaglione, S. et. al., J. Clin. Gastroenterol. (2015); HE Practice Guidelines by AASLD and EASL (2014); DelveInsight – HE Market Forecast (2019). 2. Based on currently marketed products only with potential for further ex
Slide 26: AXA1665 - A Potential Comprehensive OHE Therapy
© 2022 Axcella Therapeutics. All rights reserved. Hypothesized mechanisms depicted above. Abbreviations: Asp, aspartate; Cit, citrulline; Gln, glutamine; Glu, glutamic acid; His, histidine; Ile, isoleucine; Leu, leucine; Lys, lysine; Met, methionine; mTORC1, mammalian target of rapamycin complex 1;
Slide 27: AXA1665-002: Improvement Noted in Key Biomarkers
© 2022 Axcella Therapeutics. All rights reserved. -30 -15 0 15 30 45 60 75 BL W2 W4 W6 W9 W12 P e rc e n ta g e C h a n g e , L S M e a n ( S E ) 1. 11, 22 and 27 subjects in placebo, AXA1665 low-dose, and AXA1665 high-dose arms, respectively, were included in the analysis; LS = Least-squares; AXA16
Slide 28: Dose Dependent Improvement Across Three Measures of Cognitive Function
© 2022 Axcella Therapeutics. All rights reserved. -3 0 3 6 A b s o lu te c h a n g e , L S m e a n ( S E ), H z -0.0 -0.3 2.6 1. Considered to be a clinically relevant threshold based on PHES improvements ranging from 2.1 to 3.2 for lactulose, probiotics and LOLA in prior clinical trials. Singh, J,
Slide 29: Phase 2 Clinical Trial Underway
© 2022 Axcella Therapeutics. All rights reserved. NC: neurocognitive; fxn: function; PROs: patient reported outcomes; SOC: standard of care (lactulose ± rifaximin) Phase 2 Clinical Trial Underway Efficient design to measure PHES, OHE event rates, physical function, PROs Screening 1:1 Randomization (
Slide 30: Summary
© 2022 Axcella Therapeutics. All rights reserved. Summary 30
Slide 31: Strategy Intended to Protect Axcella's First-Mover Advantages
© 2022 Axcella Therapeutics. All rights reserved. 0 3 9 12/31/17 12/31/19 12/31/21 33 127 277 12/31/17 12/31/19 12/31/21 11 18 21 12/31/17 12/31/19 12/31/21 Strategy Intended to Protect Axcella’s First-Mover Advantages WORLDWIDE PATENT FAMILIES WORLDWIDE PATENTS PENDING U.S. PATENTS GRANTED PATENTS
Slide 32: Axcella Financials
© 2022 Axcella Therapeutics. All rights reserved. Axcella Financials $66 million in cash and marketable securities at September 30 (in thousands) September 30, 2021 Assets: Cash and cash equivalents $26,091 Marketable securities 40,055 Other assets 2,675 Total assets $68,821 Liabilities and stockhol
Slide 33: Axcella's Experienced Leadership
© 2022 Axcella Therapeutics. All rights reserved. Axcella’s Experienced Leadership BOARD OF DIRECTORS David Epstein (Chairman) Executive Partner Flagship Pioneering Stephen Hoge, MD President Moderna Therapeutics William “Chip” Baird CFO 2seventy bio Catherine A. Sohn, PharmD Adjunct Professor Unive
Slide 34: Thank You
© 2022 Axcella Therapeutics. All rights reserved. NASDAQ: AXLA 840 Memorial Drive, Third Floor Cambridge, MA 02139 www.axcellatx.com Thank You
Slide 35: Reference Materials
© 2022 Axcella Therapeutics. All rights reserved. Reference Materials Axcella’s EMM Platform and Therapeutic Approach Use of Amino Acids as Therapeutics (iScience) Combinatorial approach to EMMs (ICFSR) AXA1665 for OHE AXA1665-001 Data (Clinical and Translational Gastroenterology) AXA1665-002 Data (
Slide 36: About Axcella's Development Model and Clinical Approach
© 2022 Axcella Therapeutics. All rights reserved. About Axcella’s Development Model and Clinical Approach EMMs have a fundamental role in biology and biological function. Using the Axcella Knowledge Base, Axcella designs and develops novel EMM compositions to engage identified biologies and pathways
Axcella Health — Investor Presentation (January 2022) on 6ix